Company Overview
Company Type: Public Company
Website: www.helixbiopharma.com
Number of Employees: 7
Ticker: HBP (TSX)
Year Founded: -


Business Description
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
45.5
EBITDA
(5.3)
Total Enterprise Value
44.2
TEV/EBITDA
NM
EBIT
(5.3)
Cash & ST Invst.
1.3
P/Diluted EPS Before Extra
NM
Net Income
(5.5)
Total Debt
0.0
Price/Tang BV
46.0x
Capital Expenditure
0.0
Total Assets
1.6
Currency in CAD in mm, LTM as of Apr-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Antas, Jacek 
CEO & Director
Kawar, Hatem 
Chief Financial Officer
Siegers, Gabrielle M.
Head of R&D
Malhotra, Namrata 
Corporate Secretary

Key Board Members
Name
Title
Antas, Jacek 
CEO & Director
Leszczynski, Jerzy 
Independent Director
Grabski, Janusz 
Director
Laube, Malgorzata Irena
Independent Director
Renshaw, Frank Gary
Chief Medical Officer & Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
401 Bay Street Suite 2704 PO Box 4 | Toronto, ON | M5H 2Y4 | Canada
Fax: 905 841 2244

Current and Pending Investors
CAIAC Fund Management AG, Icahn Capital LP, Sherfam Inc., The Lind Partners, LLC

Prior Investors
Discovery Capital Corporation

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.21
Market Cap (mm)
45.5
Open
 0.21
Shares Out. (mm)
216.7
Previous Close
 0.21
Float %
81.9%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(4.5)%
Dividend Yield %
-
Day High/Low
 0.21/ 0.21
Diluted EPS Excl. Extra Items
(0.03)
52 wk High/Low
 0.26/ 0.19
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0005
Avg 3M Dly Vlm (mm)
0.0057
Beta 5Y
(0.67)


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Sensium Technologies, Inc.
Sensium Technologies Inc., a subsidiary of Helix Biopharma Corp., develops biofunction chip technologies. The company's technology includes isolation and manipulation of the cellular machinery upon receptors, and screening for therapeutic compounds, which affect the cellular machinery and prevent diseases. Sensium Technologies Inc. was founded in 1998 and is based in Aurora, Ontario.

United States and Canada
Life Sciences Tools and Services
-
-
-
PharmaDerm Laboratories Ltd.
PharmaDerm Laboratories Ltd. develops drugs. The company was founded in 1991 and is based in Saskatoon, Canada. As of November, 3, 2011 PharmaDerm Laboratories Ltd. operates as a subsidiary of Helix Biopharma Corp.

United States and Canada
Pharmaceuticals
-
-
-
Intercon Pharma Limited

-
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-22-2023
-
Private Placement
Target
Helix BioPharma Corp. (TSX:HBP)


2.21
Sep-12-2022
Oct-31-2022
Private Placement
Target
Helix BioPharma Corp. (TSX:HBP)


3.39
Apr-13-2022
Apr-21-2022
Private Placement
Target
Helix BioPharma Corp. (TSX:HBP)


1.60
Mar-11-2022
Mar-11-2022
Private Placement
Target
Helix BioPharma Corp. (TSX:HBP)


0.79
May-11-2021
May-13-2021
Private Placement
Target
Helix BioPharma Corp. (TSX:HBP)
The Lind Partners, LLC Buyer Funds:Lind Global Macro Fund, LP

2.88
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-22-2023
Executive/Board Changes - Other
Helix BioPharma Corp. Announces Executive Changes
Aug-22-2023
Private Placements
Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in funding
Jan-24-2023
Auditor Changes
Helix BioPharma Corp. Appoints Clearhouse LP as Auditor
Jan-24-2023
Shareholder/Analyst Calls
Helix BioPharma Corp. - Shareholder/Analyst Call
Jan-24-2023
Annual General Meeting
Helix BioPharma Corp., Annual General Meeting, Jan 24, 2023

M&A Advisors
ACM Alpha Consulting Management Est., Osler, Hoskin & Harcourt LLP, PricewaterhouseCoopers Corporate Finance LLC


Advisors
Most Recent Auditor
Marcum LLP
M&A Advisors
ACM Alpha Consulting Management Est., Osler, Hoskin & Harcourt LLP, PricewaterhouseCoopers Corporate Finance LLC
Private Placement Advisors
ACM Alpha Consulting Management AG, Investment Banking Arm, ACM Alpha Consulting Management Est., Alpha Management Consulting LLC
Key development Advisor
Cantor Fitzgerald & Co.


Most Recent Auditor
Marcum LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:17 AM
HBP
Helix Biopharma Corp 2023_10_05
Reports
14
GlobalData

Oct 05, 2023 01:43 AM
HBP
Helix BioPharma Corp (HBP.TSE) - Financial and Strategic SWOT Analysis Review
Reports
234
ValuEngine, Inc.

Oct 02, 2023 06:16 AM
HBP
ValuEngine - Toronto Quantitative Stock Report for HBP
Reports
5
The Economy Matters

Oct 02, 2023 03:02 AM
HBP
The Economy Matters
Reports
8
GlobalData

Sep 20, 2023 03:07 AM
HBP
Helix BioPharma Corp (HBP.TSE) - Financial and Strategic SWOT Analysis Review
Reports
233
GlobalData

Sep 15, 2023 09:54 AM
HBP
Helix BioPharma Corp (HBP.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
128
S&P Global Compustat

Sep 07, 2023 02:59 AM
HBP
Helix Biopharma Corp 2023_09_07
Reports
14
GlobalData

Aug 18, 2023 03:43 AM
HBP
Helix BioPharma Corp (HBP.FRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
90
S&P Global Compustat

Jul 06, 2023 02:40 AM
HBP
Helix Biopharma Corp 2023_07_06
Reports
14
GlobalData

Jun 28, 2023 04:06 AM
HBP
Helix BioPharma Corp (HBP.FRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
90


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Wilczewski, Jerzy 

33,944,931

15.67

7.1

Aug-21-2023


CAIAC Fund Management AG

26,363,172

12.17

5.5

Dec-12-2022


Antas, Jacek 

3,191,600

1.47

0.7

Jan-09-2023


Leszczynski, Jerzy 

2,083,344

0.96

0.4

Aug-21-2023


Maciejewski, Christopher 

0

0.00

0.0

Aug-21-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Wilczewski, Jerzy 
33,944,931
2,777,778
Leszczynski, Jerzy 
2,083,344
400,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Maciejewski, Christopher 
0
(680,036)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Biphasix Topical Formulation System, CAR-T (Future), Distribution of Imunovir, Distribution of Monovisc, Distribution of Normacol, Distribution of Orthovisc, L-DOS47 (Future), Licensing of Biochip Technology Products, Licensing of Biphasix Topical Formulation System, Licensing of Klean-Prep Products, Licensing of V-DOS47, Topical Interferon Alpha-2b, V-DOS47 (Future)


Upcoming Events
Date/Time
Type
Oct-30-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-22-2023
-
Helix BioPharma Corp. (TSX:HBP)
SEDAR
News Releases
553 KB
Jun-14-2023
-
Helix BioPharma Corp. (TSX:HBP)
SEDAR
News Releases
236 KB
Jun-14-2023
Apr-30-2023
Helix BioPharma Corp. (TSX:HBP)
SEDAR
Interim Financial Statements
426 KB
Mar-15-2023
-
Helix BioPharma Corp. (TSX:HBP)
SEDAR
News Releases
474 KB
Mar-15-2023
Jan-31-2023
Helix BioPharma Corp. (TSX:HBP)
SEDAR
Interim Financial Statements
460 KB
Jan-24-2023
-
Helix BioPharma Corp. (TSX:HBP)
SEDAR
News Releases
233 KB
Jan-24-2023
-
Helix BioPharma Corp. (TSX:HBP)
SEDAR
Management Proxy Materials
162 KB
Jan-09-2023
-
Helix BioPharma Corp. (TSX:HBP)
SEDAR
News Releases
543 KB
Dec-23-2022
-
Helix BioPharma Corp. (TSX:HBP)
SEDAR
Documents Affecting the Rights of Security Holders
165 KB
Dec-23-2022
-
Helix BioPharma Corp. (TSX:HBP)
SEDAR
Management Proxy Materials
569 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Wilczewski, Jerzy 
Aug-21-2023
Common Shares
2,777,778
504,411
Private Acquisition
8.91
Multiple
Leszczynski, Jerzy  (Independent Director)
Aug-21-2023
Common Shares
400,000
72,635
Private Acquisition
23.76
Multiple
Leszczynski, Jerzy  (Independent Director)
Nov-03-2022
Common Shares
400,000
71,689
Private Acquisition
31.17
Multiple
Antas, Jacek  (CEO & Director)
Nov-03-2022
Common Shares
1,100,000
197,145
Private Acquisition
52.59
Multiple
Wilczewski, Jerzy 
Apr-22-2022
Common Shares
7,700,000
2,155,965
Private Acquisition
32.81
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Antas, Jacek 
CEO & Director
-
905 841 2244

Leszczynski, Jerzy 
Independent Director
-
905 841 2244

Grabski, Janusz 
Director
-
905 841 2244

Laube, Malgorzata Irena
Independent Director
-
905 841 2244

Renshaw, Frank Gary
Chief Medical Officer & Member of Scientific Advisory Board
-
905 841 2244

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Antas, Jacek 
CEO & Director
-
905 841 2244

Kawar, Hatem 
Chief Financial Officer
-
905 841 2244

Siegers, Gabrielle M.
Head of R&D
-
905 841 2244

Malhotra, Namrata 
Corporate Secretary
-
905 841 2244
namrata@grovecorp.ca
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
